Roflumilast

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

COPD

Conditions

COPD

Trial Timeline

Dec 15, 2013 → Sep 16, 2022

NCT ID

NCT03381573

About Roflumilast

Roflumilast is a pre-clinical stage product being developed by AstraZeneca for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT03381573. Target conditions include COPD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03381573	Pre-clinical	Completed	Dec 15, 2013	Sep 16, 2022	COPD
NCT02068456	Pre-clinical	Completed	Sep 18, 2012	Apr 26, 2017	Chronic Obstructive Pulmonary Disease
NCT01354782	Phase 1	Completed	May 1, 2011	Sep 1, 2011	Chronic Obstructive Pulmonary Disease
NCT01140542	Phase 2	Completed	Aug 1, 2006	Mar 1, 2008	Diabetes Mellitus Type 2
NCT00246935	Phase 3	Completed	May 1, 2005	Oct 1, 2007	Chronic Obstructive Pulmonary Disease (COPD)
NCT00246922	Phase 3	Completed	Dec 1, 2004	Oct 1, 2007	Bronchial Asthma
NCT00242294	Phase 2/3	Completed	Nov 1, 2004	Mar 1, 2007	Chronic Obstructive Pulmonary Disease (COPD)
NCT00108823	Phase 3	Completed	Oct 1, 2004	—	Chronic Obstructive Pulmonary Disease, COPD
NCT00242307	Phase 2/3	Completed	May 1, 2004	Jun 1, 2007	Bronchial Asthma
NCT00163475	Phase 3	Completed	May 1, 2004	Aug 1, 2005	Asthma
NCT00076076	Phase 3	Completed	Dec 1, 2003	Jun 1, 2005	Asthma
NCT00076089	Phase 3	Completed	Dec 1, 2003	Dec 1, 2005	Chronic Obstructive Pulmonary Disease
NCT00073177	Phase 3	Completed	Nov 1, 2003	—	Asthma
NCT00062582	Phase 3	Completed	Jun 1, 2003	—	Chronic Obstructive Pulmonary Disease
NCT00163527	Phase 3	Completed	Apr 1, 2003	Nov 1, 2005	Asthma
NCT00430729	Phase 3	Completed	Jan 1, 2003	—	Chronic Obstructive Pulmonary Disease

Competing Products

20 competing products in COPD

See all competitors

Product	Company	Stage	Hype Score
Sitafloxacin + Moxifloxacin Hydrochloride	Daiichi Sankyo	Approved	85
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	52
Lysozyme hydrochloride + Placebo	Eisai	Approved	85
Arformoterol (Brovana) + Placebo	Sumitomo Pharma	Approved	85
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + Placebo	Sumitomo Pharma	Phase 3	77
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo	Sumitomo Pharma	Phase 2	52
Arformoterol tartrate inhalation solution + Tiotropium	Sumitomo Pharma	Approved	85
Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterol	Sumitomo Pharma	Phase 2	52
Levalbuterol HCl + Levalbuterol HCl + Albuterol Sulfate + Placebo	Sumitomo Pharma	Phase 3	77
Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler	AstraZeneca	Phase 1	33
AZD2115 + Placebo + Indacaterol + Indacaterol + Tiotropium	AstraZeneca	Phase 2	52
Roflumilast	AstraZeneca	Phase 2/3	65
Aclidinium bromide + Placebo	AstraZeneca	Phase 3	77
Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)	AstraZeneca	Approved	85
AZD7624 + Placebo to match	AstraZeneca	Phase 1	33
Roflumilast + Placebo	AstraZeneca	Phase 3	77
Aclidinium bromide 100 μg bid + Aclidinium bromide 200 μg bid + Aclidininum bromide 400 μg bid + Placebo + Formoterol 12 μg bid	AstraZeneca	Phase 2	52
ACL/FOR + Placebo	AstraZeneca	Approved	85
Tozorakimab	AstraZeneca	Phase 2	52
AZD1981 + Placebo	AstraZeneca	Phase 2	52

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved